Treatment failure · adults with drug‐sensitive pulmonary tuberculosis
Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in treatment failure compared with standard 6‐month ATT regimen (moderate certainty).
1 finding from 1 review
Acquired drug resistance · adults with drug‐sensitive pulmonary tuberculosis
Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in acquired drug resistance compared with standard 6‐month ATT regimen (low certainty).
1 finding from 1 review
Treatment failure · adults with drug‐sensitive pulmonary tuberculosis
Gatifloxacin‐containing 4‐month ATT regimens showed no clear difference in treatment failure compared with standard 6‐month ATT regimens (moderate certainty).
1 finding from 1 review
Acquired drug resistance · adults with drug‐sensitive pulmonary tuberculosis
It is very uncertain whether gatifloxacin‐containing 4‐month ATT regimens changes acquired drug resistance compared with standard 6‐month ATT regimens (very low certainty).
1 finding from 1 review
Duration of diarrhoea · Adults and children with cholera diarrhoea
1 finding from 1 review
Stool volume · Adults and children with cholera diarrhoea
1 finding from 1 review
Hydration fluid requirements · Adults and children with cholera diarrhoea
1 finding from 1 review
Duration of pathogen secretion · Adults and children with cholera diarrhoea
1 finding from 1 review
Deaths · Adults and children with cholera diarrhoea
1 finding from 1 review
Treatment failure · drug‐resistant pulmonary tuberculosis
It is very uncertain whether linezolid changes treatment failure compared with no linezolid (very low certainty).
1 finding from 1 review
Treatment interrupted · drug‐resistant pulmonary tuberculosis
It is very uncertain whether linezolid changes treatment interrupted compared with no linezolid (very low certainty).
1 finding from 1 review
Number of women who completed treatment ‐ total · drug‐resistant pulmonary tuberculosis
It is very uncertain whether linezolid changes treatment completed compared with no linezolid (very low certainty).
1 finding from 1 review
Antituberculous treatment discontinuationj · drug‐resistant pulmonary tuberculosis
It is very uncertain whether linezolid changes antituberculous treatment discontinuationj compared with no linezolid (very low certainty).
1 finding from 1 review
Treatment failure · Patients with presumed drug‐sensitive TB
1 finding from 1 review
Treatment failure · Patients with presumed drug‐sensitive TB
1 finding from 1 review
Treatment failure · Patients with presumed drug‐sensitive TB
1 finding from 1 review
Intervention not reported
Treatment failure · antiretroviral‐naïve individuals
The intervention showed no clear difference in treatment failure (low certainty).
1 finding from 1 review
Serious adverse events attributable to the drug · people with confirmed COVID‐19
Favipiravir showed no clear difference in serious adverse events attributable to the drug compared with no treatment, supportive treatment, or other antiviral treatment (low certainty).
1 finding from 1 review
Intervention not reported
Clinical failure 1 to 14 days after end of treatment · adults and children with amoebic colitis
It is very uncertain whether the intervention changes clinical failure 1 to 14 days after end of treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Parasitological failure 1 to 14 days after end of treatment Method: stool microscopy demonstrating E histolytica cysts or trophozoites · adults and children with amoebic colitis
The intervention may leads to lower parasitological failure 1 to 14 days after end of treatment Method:… (low certainty).
1 finding from 1 review